KRRO — Korro Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1703647 ·
Last close
$12.32
Market Cap
$169.10M
52W High
$17.35
52W Low
$5.20
ADV30
215,321
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -18,456,000 | -17,548,000 | 148,120,000 | 40,215,000 | 59,746,000 |
| Jun 2026 | 0 | — | -20,110,000 | -18,916,000 | 163,446,000 | 24,905,000 | 60,220,000 |
| Mar 2026 | 0 | — | -20,436,000 | -19,625,000 | 183,622,000 | 61,697,000 | 63,989,000 |
| Dec 2025 | 1,292,000 | — | -15,883,000 | -50,042,000 | 113,506,000 | 21,824,000 | 62,067,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-63,705,000
Investing CF
$-6,965,000
Financing CF
$85,675,000
CapEx
$-169,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.66
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-439,935,000
Inventory
—
Receivables
$0
ST Investments
$64,779,000
EBIT TTM
$-74,885,000
Pretax Income TTM
$-105,032,000
Interest Exp TTM
—
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,292,000
EBITDA
$-74,366,000
Free Cash Flow
$-43,673,000
Enterprise Value
$138,982,272
Total Cash
$104,994,000
Total Debt
$41,523,000
Shares Out
13,725,646
Trailing EPS
$-8.89
Book Value
$6.44
ROE
-113.3%
ROA
-30.7%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 6,392,000 | -87,342,000 | -117,260,000 | 113,506,000 | 62,067,000 | 51,439,000 | -78,561,000 |
| Dec 2024 | 2,271,000 | -91,910,000 | -83,581,000 | 226,240,000 | 65,825,000 | 160,415,000 | -60,074,000 |
| Dec 2023 | 0 | -84,534,000 | -81,172,000 | 221,663,000 | 51,752,000 | 169,911,000 | -67,283,000 |
| Dec 2022 | 0 | -58,998,000 | -58,032,000 | 73,742,000 | 172,773,000 | -99,031,000 | -53,645,000 |
TTM Snapshot
Revenues TTM
$2,382,000
NetIncome TTM
$-106,644,000
OpCashFlow TTM
—
Assets (Latest)
$163,446,000
Forward EPS
$-4.27
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $17.50 · spot: $12.44 · call volume: 16 · put volume: 23
Expected Move to 2026-12-18:
±$5.00
(40.19%) —
implied range
$7.44 –
$17.44
· ATM straddle on $12.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IFRX | InflaRx N.V. | $169.47M | $1.15 | — |
| ORMP | ORAMED PHARMACEUTICALS INC. | $168.29M | $3.87 | — |
| ELDN | Eledon Pharmaceuticals, Inc. | $167.23M | $1.98 | — |
| PYXS | Pyxis Oncology, Inc. | $172.24M | $1.44 | — |
| SLGL | Sol-Gel Technologies Ltd. | $172.97M | $52.83 | — |
News headlines (Yahoo Finance, 1h cache)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-13 21:05 · Yahoo
Korro to Present at the 2026 Jefferies Global Healthcare Conference in London
2026-11-06 12:00 · Yahoo
Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-05 12:00 · Yahoo
Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
2026-10-23 09:47 · Yahoo
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
2026-10-22 11:00 · Yahoo
Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-16 20:05 · Yahoo
Korro to Participate in Upcoming Investor Conferences
2026-08-27 11:00 · Yahoo
Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 11:00 · Yahoo
Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?
2026-07-08 16:00 · Yahoo
Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
2026-06-19 12:06 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.